Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treat...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2015/629046 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555345240653824 |
|---|---|
| author | Michela Roberto Maria Bassanelli Elsa Iannicelli Silvana Giacinti Chiara D’Antonio Anna Maria Aschelter Paolo Marchetti |
| author_facet | Michela Roberto Maria Bassanelli Elsa Iannicelli Silvana Giacinti Chiara D’Antonio Anna Maria Aschelter Paolo Marchetti |
| author_sort | Michela Roberto |
| collection | DOAJ |
| description | Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treatments also allow stabilization of clinical symptomatology. However, validated treatment guidelines for RCC patients with brain metastases are not yet available on account of the frequent exclusion of such patients from clinical trials. Moreover, limited data about the sequential use of three therapies, changing the class of agent, have been published up to now. Case Report. We report the case of a patient with metastatic RCC who developed disease progression after sunitinib and everolimus as first-line and second-line therapy, respectively. Thus, he underwent a multimodality treatment with pazopanib, as third-line therapy, to control systemic disease and radiosurgery directed on the new brain metastasis. To date, the patient is still receiving pazopanib, with progression-free survival and overall survival of 43 and 103 months, respectively. Conclusion. In a context characterized by different emerging options, with no general consensus on the optimal treatment strategy, the use of pazopanib in pretreated patients could be a suitable choice. |
| format | Article |
| id | doaj-art-82c004c9a2f94422b5ec8f5a13c0468e |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-82c004c9a2f94422b5ec8f5a13c0468e2025-02-03T05:48:27ZengWileyCase Reports in Oncological Medicine2090-67062090-67142015-01-01201510.1155/2015/629046629046Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell CarcinomaMichela Roberto0Maria Bassanelli1Elsa Iannicelli2Silvana Giacinti3Chiara D’Antonio4Anna Maria Aschelter5Paolo Marchetti6Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, ItalyDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, ItalyDepartment of Radiology, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, ItalyDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, ItalyDepartment of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, ItalyDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, ItalyDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, ItalyBackground. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treatments also allow stabilization of clinical symptomatology. However, validated treatment guidelines for RCC patients with brain metastases are not yet available on account of the frequent exclusion of such patients from clinical trials. Moreover, limited data about the sequential use of three therapies, changing the class of agent, have been published up to now. Case Report. We report the case of a patient with metastatic RCC who developed disease progression after sunitinib and everolimus as first-line and second-line therapy, respectively. Thus, he underwent a multimodality treatment with pazopanib, as third-line therapy, to control systemic disease and radiosurgery directed on the new brain metastasis. To date, the patient is still receiving pazopanib, with progression-free survival and overall survival of 43 and 103 months, respectively. Conclusion. In a context characterized by different emerging options, with no general consensus on the optimal treatment strategy, the use of pazopanib in pretreated patients could be a suitable choice.http://dx.doi.org/10.1155/2015/629046 |
| spellingShingle | Michela Roberto Maria Bassanelli Elsa Iannicelli Silvana Giacinti Chiara D’Antonio Anna Maria Aschelter Paolo Marchetti Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma Case Reports in Oncological Medicine |
| title | Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma |
| title_full | Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma |
| title_fullStr | Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma |
| title_full_unstemmed | Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma |
| title_short | Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma |
| title_sort | clinical outcome of third line pazopanib in a patient with metastatic renal cell carcinoma |
| url | http://dx.doi.org/10.1155/2015/629046 |
| work_keys_str_mv | AT michelaroberto clinicaloutcomeofthirdlinepazopanibinapatientwithmetastaticrenalcellcarcinoma AT mariabassanelli clinicaloutcomeofthirdlinepazopanibinapatientwithmetastaticrenalcellcarcinoma AT elsaiannicelli clinicaloutcomeofthirdlinepazopanibinapatientwithmetastaticrenalcellcarcinoma AT silvanagiacinti clinicaloutcomeofthirdlinepazopanibinapatientwithmetastaticrenalcellcarcinoma AT chiaradantonio clinicaloutcomeofthirdlinepazopanibinapatientwithmetastaticrenalcellcarcinoma AT annamariaaschelter clinicaloutcomeofthirdlinepazopanibinapatientwithmetastaticrenalcellcarcinoma AT paolomarchetti clinicaloutcomeofthirdlinepazopanibinapatientwithmetastaticrenalcellcarcinoma |